Download PDF
Drug Res (Stuttg) 2014; 64(08): 412-419
DOI: 10.1055/s-0033-1358748
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Simple and Rapid Determination of Zafirlukast in Plasma by Ultra-performance Liquid Chromatography Tandem Mass Spectrometric Method: Application into Pharmacokinetic Study in Rabbits

M. Iqbal
1   Bioavailability Laboratory, College of Pharmacy, King Saud University, Riyadh, KSA
2   Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, KSA
,
E. Ezzeldin
1   Bioavailability Laboratory, College of Pharmacy, King Saud University, Riyadh, KSA
,
K. A. Al-Rashood
2   Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, KSA
,
K. I. Al-khamees
3   Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, KSA
,
R. M. A. Khan
3   Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, KSA
,
M. Raish
4   Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, KSA
,
T. Anwer
5   Department of Pharmacology, College of Pharmacy, Jazan University, Jazan, KSA
› Author Affiliations
Further Information

Publication History

received 28 August 2013

accepted 29 October 2013

Publication Date:
20 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Zafirlukast is a selective leukotriene receptor antagonist used for the prophylaxis and chronic treatment of asthma. The aim of the present study was to develop a simple sensitive ultra-performance liquid chromatography tandem mass spectroscopy method for rapid determination of zafirlukast in plasma. After a simple one step protein precipitation by acetonitrile, zafirlukast and montelukast (IS) were separated on Acquity UPLC BEHTM C18 column (50×2.1 mm, i.d. 1.7 µm, Waters, USA) using a mobile phase of acetonitrile:water containing 10 mM acetic acid (80:20, v/v) at a flow rate of 0.3 mL/min. Zafirlukast and IS were eluted at 0.51 and 1.1 min, respectively with a total run time of only 1.5 min. The mass spectrometric determination was carried out using an electrospray interface operated in the negative mode with multiple reactions monitoring mode. The precursor to product ion transitions of m/z 574.11>462.07 and m/z 584.2>472.1 were used to quantify zafirlukast and IS, respectively. The method was linear in the concentration range of 0.17–600 ng/mL with coefficients of determination greater than 0.996 and lower limit of quantitation of 0.17 ng/mL. Intra-day and inter-day accuracies were 88.3–113.9% and the precisions were ≤12.6%. Zafirlukast was found to stable under various storage and sample processing conditions as per guidelines of bio-analytical method validation. The method developed herein is simple and rapid, and was successfully applied for the pharmacokinetic study in rabbits.

Key words

zafirlukast - ultra performance liquid chromatography - tandem mass spectrometry - pharmacokinetics - high throughput analysis
 

  • References

  • 1 Prescribing information of ACCOLATE (zafirlukast) AstraZeneca Pharmaceuticals LP, UK. Downloaded from http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c (accessed on April 13, 2013)
    PubMed
  • 2 Fischer JD, Song MH, Suttle AB et al. Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans. Pharmceutical Research 2000; 17: 154-159
    PubMedSearch in Google Scholar
  • 3 Shubha R, Swati G, Anjali Z et al. Zafirlukast Pharmacokinetics in Healthy Indian Male Subjects: Interethnic Variability. Indian Journal of Allergy Asthma Immunol 2005; 19: 69-73
    PubMedSearch in Google Scholar
  • 4 Dekhuijzen PN, Koopmans PP. Pharmacokinetic profile of zafirlukast. Clinical Pharmacokinetics 2002; 41: 105-114
    CrossrefPubMedSearch in Google Scholar
  • 5 Ficarra R, Ficarra P, Tommasini S et al. Validation of a LC method for the analysis of zafirlukast in a pharmaceutical formulation. J Pharm Biomedical Analysis 2000; 23: 169-174
    PubMedSearch in Google Scholar
  • 6 Radhakrishna T, Satyanarayana J, Satyanarayana A. Determination of zafirlukast by stability indicating LC and derivative spectrophotometry. J Pharm Biomedical Analysis 2002; 30: 695-703
    PubMedSearch in Google Scholar
  • 7 Suslu I, Altinoz S. A reversed-phase high-performance liquid chromatographic method for the determination of ZFR in pharmaceutical formulations and human plasma. J AOAC International 2006; 89: 1557-1564
    PubMedSearch in Google Scholar
  • 8 Süslü I, Demircan S, Altinöz S et al. Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulations. J Pharm Biomed Anal 2007; 44: 16-22
    CrossrefPubMedSearch in Google Scholar
  • 9 Süslü I, Altinöz S. Electrochemical characteristics of zafirlukast and its determination in pharmaceutical formulations by voltammetric methods. J Pharm Biomedical Analysis 2005; 39: 535-542
    PubMedSearch in Google Scholar
  • 10 Goverdhan G, Reddy AR, Srinivas K et al. Identification, characterization and synthesis of impurities of zafirlukast. J Pharm Biomedical Analysis 2009; 49: 895-900
    PubMedSearch in Google Scholar
  • 11 Thiyagarajan TK, Abdul Hakeem JA, Baksam V. Development of a stability-indicating RP-LC method for the separation of a critical pair of impurities and their degradants in zafirlukast. J Chromatogrphy Science 2012; 50: 945-952
    PubMedSearch in Google Scholar
  • 12 Bui KH, Kennedy CM, Azumaya CT et al. Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection. J Chromatogrphy B Biomedical Science Appl 1997; 696: 131-136
    PubMedSearch in Google Scholar
  • 13 Bharathi DV, Naidu A, Jagadeesh B et al. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. Biomedical Chromatography 2008; 22: 645-653
    CrossrefPubMedSearch in Google Scholar
  • 14 Guideline on bioanalytical method validation European Medicines Agency, EMEA/CHMP/EWP192217/2009. 1 February 2012 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (accessed April 19, 2013)
    PubMed
  • 15 Guidance for Industry on Bioanalytical Method Validation . US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Rockville, MD: Department of Health and Human Services; 2001
    Search in Google Scholar
  • 16 Wu Z, Gao W, Phelps MA et al. Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Analytical Chemistry 2004; 76: 839-847
    CrossrefPubMedSearch in Google Scholar